Kerri-Ann Limbeek, partner at Desmarais and trial lead for Ravgen.
25 January 2024FeaturesBig PharmaSarah Speight
Trial-focused: Lead counsel on how a strong story helped Ravgen defeat Natera
Last week, a US jury found that prenatal screening technology owned by one biotech firm Natera infringed a patent held by a rival, awarding damages of $57 million.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
24 December 2020 Biotechnology company Ravgen has accused Myriad Genetics and Myriad Women’s Health of infringing two patents covering non-invasive DNA testing technology.
18 January 2024 Dispute centres on genetic prenatal screening methodology | Ravgen’s $57 million award “significantly less” than the $410 million sought by Ravgen | Natera plans to appeal.
24 December 2020 Biotechnology company Ravgen has accused Myriad Genetics and Myriad Women’s Health of infringing two patents covering non-invasive DNA testing technology.
18 January 2024 Dispute centres on genetic prenatal screening methodology | Ravgen’s $57 million award “significantly less” than the $410 million sought by Ravgen | Natera plans to appeal.
24 December 2020 Biotechnology company Ravgen has accused Myriad Genetics and Myriad Women’s Health of infringing two patents covering non-invasive DNA testing technology.
18 January 2024 Dispute centres on genetic prenatal screening methodology | Ravgen’s $57 million award “significantly less” than the $410 million sought by Ravgen | Natera plans to appeal.
